Targeted Protein Degradation for CNS

Following proof of concept in oncology, misfolded and aggregated pathological proteins across CNS indications are the new frontier for protein degradation technologies.

Heading to Boston, the Targeted Protein Degradation for CNS Summit is uniting 50+ experts with 3-days of industry-focused content solely dedicated to delivering and translating TPD technologies to degrade undruggable extracellular and intracellular CNS proteins.

Don't miss your chance to join industry leaders pioneering the exploration of PROTACs, AUTOTACs, molecular glues, and more revolutionary TPD technologies against CNS targets.

This is your only chance to attend an industry-focused meeting dedicated to showcasing early CNS biopharma investment and overcoming your challenges to translate safe and efficacious protein degraders into the clinic for neurology patients.

What's in store?

Discover the state-of-the-art preclinical CNS protein degrader development and navigate considerations for future CNS degrader clinical trials with Arvinas

Understand development of AUTOTACs and alternative degraders to target extracellular CNS aggregates via autophagy-mediated degradation with AUTOTAC Bio and PAQ Therapeutics

Break down degrader properties and translatable learnings from neuro-oncology to accelerate and optimize degrader delivery across the BBB with Nurix Therapeutics and DFCI

Evaluating PROTAC pharmacokinetics, achievable brain exposure and off-target degradation to optimize CNS degrader translation with Genentech

Discuss the pitfalls in protein degrader assays to brainstorm CNS-specific assay considerations with AstraZeneca

Download full event guide - https://ter.li/xx10pr

Register to attend - https://ter.li/qanqc0

URLs:
Website: https://go.evvnt.com/1927651-0?pid=10018
Tickets: https://go.evvnt.com/1927651-2?pid=10018
Brochure: https://go.evvnt.com/1927651-3?pid=10018

Prices:
Conference Only - Drug Developer : USD 2599.00,
Conference + 1 Workshop - Drug Developer: USD 3098.00,
Full Conference Access - Drug Developer: USD 3597.00,
Conference Only - Solution Provider: USD 3799.00
Conference + 1 Workshop - Solution Provider: USD 4548.00
Full Conference Access - Solution Provider: USD 5297.00

Speakers: Andrew Zhang - Director - AstraZeneca, Bart Westerman - Assistant Professor - Amsterdam UMC, Beth Hoffman - Chief Executive Officer - Origami Therapeutics, Charlie Hao - Bicentennial Chair and Professor - Indiana University School of Medicine, Demetrios Kostomiris - Senior Research Scientist - AstraZeneca, Dong-Seok Kim - Founder and Chief Executive Officer - AevisBio, Edward Hujber - Scientist II - Plexium, Eric Masson - Senior Vice President | Early Clinical Development - Arvinas, Gwenn Hansen - Chief Scientific Officer - Nurix Therapeutics, Huaixiang Hao - Head of Biology - PAQ Therapeutics, Jonathan Baell - Executive Director | Discovery Chemistry - Lyterian Therapeutics, Marija Usenovic - Associate Principal Scientist - Merck, Natalie Prigozhina - Director | Biology - Origami Therapeutics, Patrick Wen - Director | Center for Neuro-Oncology - Dana-Farber Cancer Institute, Pietro Faccioli - Associate Professor - University of Milano-Bicocca, Robert Blake - Senior Principal Scientist | Biochemical and Cellular Pharmacology - Genentech, Simon Glerup - Chief Scientific Officer - Draupnir Bio, Yong-Tae Kwon - Chief Executive Officer - AUTOTAC Bio